Clinical trials: Vision Impairment
Macular Degeneration, Central Visual Impairment
Scotoma Perimetry Oculomotor Training
The proposed research is relevant to public health because a greater understanding of plasticity after central vision loss can inform new therapies for treating low vision and has potential to benefit millions of individuals…
- Trial name
- SPOT (NCT05456581)
- Testing
- 'Scotoma awareness' Training, Control Training
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Alabama at Birmingham
Visual Disorder, Young Adult
The Effect of Social Skills Training in Visually Impaired Adolescents
The aim of our study is to examine the effects of eight sessions of online social skills training given to visually impaired adolescents on social skills, self-efficacy, social phobia and social integration.
- Conditions
- Visual Disorder, Young Adult, Blindness, Blindness and Low Vision
- Trial name
- NCT05608811
- Testing
- Social Skills Training
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Saglik Bilimleri Universitesi
Diabetes Mellitus, Macular Edema
A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE)
This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection in patients with clinically significant macular edema with center involvement…
- Trial name
- RIDE (NCT00473382)
- Testing
- Ranibizumab
- Volunteers
- 382 people
- Sponsor
- Genentech, Inc.
Vision and Hearing Loss, Vision Impairment
SENSE-Brain Health Pro for Older Adults With Sensory Loss
The goal of this study is to learn about the outcomes, usability, and accessibility of the online Brain Health Pro program for older adults with hearing difficulties, vision difficulties, or both.
- Conditions
- Vision and Hearing Loss, Vision Impairment, Hearing Impairment, Vision Difficulty
- Trial name
- SENSE-BHPro (NCT07856888)
- Testing
- Brain Health Pro
- Where
- Canada
- Volunteers
- 300 people
- Sponsor
- Université de Montréal
Pathological Myopic Choroidal Neovascularization
601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)
To evaluate the safety and efficacy of intravitreal recombinant humanized anti-VEGF monoclonal antibody in patients with visual impairment due to pmCNV
- Trial name
- NCT04922151
- Testing
- 601, Ranibizumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Diabetic Retinopathy
Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study
This study is to test whether or not 32 milligrams (mg) of ruboxistaurin a day over three years will reduce vision loss associated with diabetic retinopathy.
- Trial name
- NCT00604383
- Testing
- ruboxistaurin
- Where
- United States
- Volunteers
- 685 people
- Sponsor
- Chromaderm, Inc.
Blindness and Low Vision
V-NAV Usability Study: End Users Trying the Vortant Indoor Navigation Tool
The study will begin with an explanatory/training session where individuals with low vision will learn to use the V-NAV (Vortant NAVigation tool) indoor navigation app, and will have the opportunity to try it for a few…
- Trial name
- NCT05647694
- Testing
- V-NAV indoor navigation prototype
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Vortant Technologies, LLC
Psychophysiology, Visually Impaired Persons
Study of Effectiveness of Audio Guided Deep Breathing on Improving the Quality of Life of Physically Disabled Group
Diaphragmatic breathing brings different advantages to improve physical and mental health but it could be difficult for the physically disabled group to follow the practice by themselves especially those with vision impairment.
- Conditions
- Psychophysiology, Visually Impaired Persons, Physiological Phenomena, Psychological Stress
- Trial name
- NCT05396027
- Testing
- Audio-guided deep breathing
- Where
- Malaysia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Universiti Tunku Abdul Rahman
Retinitis Pigmentosa
Phase 1 Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa
In this Phase 1 open-labeled prospective study, one eye of each participant with vision loss from retinitis pigmentosa will be administered intravitreal injection of autologous CD34+ stem cells harvested from bone marrow.
- Trial name
- BMSCRP1 (NCT04925687)
- Testing
- Intravitreal autologous CD34+ cells
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of California, Davis
Branch Retinal Vein Occlusion, Macular Edema
Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision
The purpose of this study is to determine the effect of ranibizumab for the treatment of macular edema (ME) secondary to branch retinal vein occlusion (BRVO) in patients with initial fair visual acuity.
- Trial name
- RVOFV (NCT01795209)
- Testing
- Ranibizumab, Rescue laser
- Where
- 2 sites in South Korea
- Volunteers
- 19 people
- Sponsor
- Seoul National University Bundang Hospital
Vision, Low, Visual Impairment
Re:Garde Program - Training and Maintaining Visual Perception in Older Adults
Seniors deal with considerable visual demands (driving, communicating, traveling) and reduced vision affects their quality of life, ability to enjoy activities, and age-in-place.
- Trial name
- Re:Garde (NCT05619432)
- Testing
- HMD: Immersive VR
- Where
- 2 sites in Canada
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Multiple Sclerosis
Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis
The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the visual improvement of patients suffering from chronic visual loss resulting from multiple sclerosis related optic neuritis.
- Trial name
- MS-ON (NCT02220244)
- Testing
- MD1003 100mg capsule
- Where
- 20 sites in France, United Kingdom
- Volunteers
- 105 people
- Sponsor
- MedDay Pharmaceuticals SA
Glaucoma, Visual Impairment
Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE
Falls are one of the most serious public health concerns for seniors, with significant medical and economic consequences. This concern is even higher in patients with peripheral field loss due to glaucoma because of the patients'…
- Trial name
- NCT06000865
- Testing
- Action video game training, Conventional physical training
- Where
- Hong Kong
- Volunteers
- 56 people
- Sponsor
- The Hong Kong Polytechnic University
Vision Impairment and Blindness, Glaucoma
Developing and Testing a Model to Identify Preventive Vision Loss Among Older Patients in General Practice
In this cohort study, the investigators will test vision screenings in Danish general practice for patients over 70 years of age with minimum one chronic condition.
- Conditions
- Vision Impairment and Blindness, Glaucoma, Age-Related Macular Degeneration, Cataract
- Trial name
- DETECT (NCT07015034)
- Testing
- focus on vision impairment in older patients in general practice
- Where
- 2 sites in Denmark
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Blindness, Visual Impairment
Physical Activity and Sports for People With Visual Impairments
Purpose of this study was to assess the relationship between the visual impairment degree and the level of children's fundamental motor skills, balance and bilateral coordination.
- Trial name
- NCT06318000
- Testing
- Balance test, bilateral coordination test, fundamental motor skills test
- Where
- Poland
- Volunteers
- 76 people
- Sponsor
- Józef Piłsudski University of Physical Education
Age Related Macular Degeneration, Central Retinal Vein Occlusion
Ziv-aflibercept in Eyes With Retinal Diseases and Poor Vision-phase I
Aflibercept is FDA approved and the same molecule is available as hyperosmolar for oncology (cost 800 USD for 4ml) and isoosmolar for Ophthalmology (cost 1,770 USD for 0.05ml injection).
- Trial name
- ZIV (NCT02173873)
- Testing
- ziv-aflibercept drug
- Where
- Lebanon
- Volunteers
- 100 people
- Sponsor
- Rafic Hariri University Hospital
Wet Macular Degeneration
OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab
In the Western World, Age Related Macular Degeneration (ARMD) is a leading cause of blindness. This disease was once thought to be a natural part of aging, but recent research has introduced effective treatments.
- Trial name
- STAR (NCT01243086)
- Testing
- Ranibizumab, OZURDEX
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- McMaster University
Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME)
Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema
This study is a prospective, non-interventional, multicenter, open-label study in nAMD and DME patients being treated with brolucizumab according to the EU SmPC.
- Trial name
- BLUE SKY (NCT04543331)
- Testing
- brolucizumab
- Where
- 41 sites in Germany
- Volunteers
- 572 people
- Sponsor
- Novartis Pharmaceuticals
Macular Degeneration, Wet Macular Degeneration
Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration
The purpose of the current study is to evaluate the ability of Eylea to induce a regression of PED height on patients previously extensively treated by Lucentis.
- Conditions
- Macular Degeneration, Wet Macular Degeneration, Retinal Degeneration, Retinal Diseases
- Trial name
- ARI2 (NCT02157077)
- Testing
- Aflibercept
- Where
- 9 sites in France
- Volunteers
- 84 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Alzheimer's Disease
Measurement of Retinal Nerve Fiber Layer Thickness - a Biomarker for the Early Detection of Alzheimer's Disease?
The purpose of this study is to determine whether by measuring changes in the thickness of the retinal nerve fibre layer (the photosensitive layer at the back of the eye) you could predict if someone would develop Alzheimer's…
- Trial name
- SCI-OCT (NCT02051244)
- Where
- Israel
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Carmel Medical Center